Event Calendar

Upcoming Events | Past Events
April 2017?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. Please select a highlighted date from the calendar to see date-specific company information, including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-6-5-4-3-2-11
2345678
9101112131415
16171819202122
2324
04/24/17
Navidea selected by NIH/NIAMS to present Rheumatoid Arthritis program to investors at Bio International in San Diego June 19-22, 2017
Navidea/Macrophage Therapeutics selected for oral presentations and The Society of Nuclear medicine and Molecular Imaging (SNMMI) Annual Meeting in Denver.
Navidea/Macrophage Therapeutics WITH Massachusetts General Hospital complete Phase 1 Pilot Study in HIV Cardiovascular disease and Presentation of Results at Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, WA, February 13-16, 2017.
Navidea/Macrophage Therapeutics and Massachusetts General Hospital publish results of Phase 1 Pilot Study of Tc99m-tilmanocpet imaging of HIV cardiovascular disease (Journal of Infectious Diseases).
Navidea/Macrophage Therapeutics and Kettering Medical Center (Dayton, OH) kick off intravenous Phase 1 dose escalation study in rheumatoid arthritis patients (NAV3-21)
Macrophage Therapeutics/Navidea Completes Three Therapeutic Animal Studies in NASH all with Positive Results.
Navidea/Macrophage Therapeutics Completes 18 Patient Rheumatoid Arthritis Diagnostic Imaging Review for Subcutaneous Tc99M-Tilmanocept Dose Escalation Study (NAV3-23).
Navidea/Macrophage Therapeutics Receives Second Round NCI SBIR Awards for Kaposi's Sarcoma (KS) Imaging and Kaposi's Sarcoma Therapy.
Navidea/Macrophage Therapeutics Completes Collaborative study of Tc99m Tilmanocept vs Filtered Sulfur Colloid Head-to-Head Study in Breast Cancer.
Navidea/Macrophage Therapeutics Completes Sentinel Node Biopsy Evaluation in Prospective Study of Tc99m Tilmanocept in Cervical Cancer.
2526272829
30515253545556
Calendar Instructions
Please select a highlighted date from the calendar to view company related information. This calendar requires JavaScript to be installed and activated on your browser.

Upcoming Events

Navidea Biopharmaceuticals Inc at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Monday, June 12, 2017 4:45 p.m. ET
Description

Navidea has been invited to present its Tc99m-tilmanocept receptor-specific diagnosis data for aortic plaques (Nav/MGH), and for rheumatoid arthritis (Nav3-21/23), at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a meeting of leading molecular imaging and nuclear medicine experts representing the world’s top medical and academic institutions and centers.

   

Time:

June 12, 4:45 - 6:15 PM – Rm 708/710 (Cardio)
June 12, 4:45 - 6:15 PM – Rm 603 (Rheumatoid)
LocationColorado Convention Center
700 14th Street
Denver, CO 80202
Add to Calendar Add Navidea Biopharmaceuticals Inc at Society of Nuclear Medicine and Molecular Imaging Annual Meeting to Calendar  Help
remind me days before the event

Navidea Biopharmaceuticals Inc at 2017 BIO International Convention
Monday, June 19, 2017
Description

Navidea has been selected by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a component of the National Institute of Health (NIH) to present its Rheumatoid Arthritis (RA) program to investors at the 2017 BIO International Convention (BIO 2017). Navidea was selected from more than 1,000 recipients of NIH/NIAMS SBIR grants to present clinical results and their commercial strategy in regards to the development of tilmanocept (Tc99m-Tilmanocept), for the diagnostic imaging of RA.

   

Event:

2017 Bio International Convention

Date:

June 19-22, 2017

Time:

TBD
LocationSan Diego Convention Center
111 W. Harbor Drive
San Diego, CA 92101
Add to Calendar Add Navidea Biopharmaceuticals Inc at 2017 BIO International Convention to Calendar  Help
remind me days before the event

Enter your e-mail address